Suppr超能文献

经颈静脉肝内门体分流术联合覆膜支架治疗门静脉癌栓型肝细胞癌

Transjugular intrahepatic portosystemic shunt with covered stents for hepatocellular carcinoma with portal vein tumor thrombosis.

作者信息

Zhao Jian-Bo, Feng Chao, Zhu Qiao-Hua, He Xiao-Feng, Li Yan-Hao, Chen Yong

机构信息

Jian-Bo Zhao, Chao Feng, Xiao-Feng He, Yan-Hao Li, Yong Chen, Department of Interventional Radiology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, Guangdong Province, China.

出版信息

World J Gastroenterol. 2014 Feb 14;20(6):1602-7. doi: 10.3748/wjg.v20.i6.1602.

Abstract

AIM

To evaluate transjugular intrahepatic portosystemic shunt (TIPS) with covered stents for hepatocellular carcinoma (HCC) with main portal vein tumor thrombus (PVTT).

METHODS

Eleven advanced HCC patients (all male, aged 37-78 years, mean: 54.3 ± 12.7 years) presented with acute massive upper gastrointestinal bleeding (n = 9) or refractory ascites (n = 2) due to tumor thrombus in the main portal vein. The diagnosis of PVTT was based on contrast-enhanced computed tomography and color Doppler sonography. The patients underwent TIPS with covered stents. Clinical characteristics and average survival time of 11 patients were analyzed. Portal vein pressure was assessed before and after TIPS. The follow-up period was 2-18 mo.

RESULTS

TIPS with covered stents was successfully completed in all 11 patients. The mean portal vein pressure was reduced from 32.0 to 11.8 mmHg (t = 10.756, P = 0.000). Gastrointestinal bleeding was stopped in nine patients. Refractory ascites completely disappeared in one patient and was alleviated in another. Hepatic encephalopathy was observed in six patients and was resolved with drug therapy. During the follow-up, ultrasound indicated the patency of the shunt and there was no recurrence of symptoms. Death occurred 2-14 mo (mean: 5.67 mo) after TIPS in nine cases, which were all due to multiple organ failure. In the remaining two cases, the patients were still alive at the 16- and 18-mo follow-up, respectively.

CONCLUSION

TIPS with covered stents for HCC patients with tumor thrombus in the main portal vein is technically feasible, and short-term efficacy is favorable.

摘要

目的

评估覆膜支架经颈静脉肝内门体分流术(TIPS)治疗伴有门静脉主干癌栓(PVTT)的肝细胞癌(HCC)的疗效。

方法

11例晚期HCC患者(均为男性,年龄37 - 78岁,平均54.3±12.7岁),因门静脉主干癌栓出现急性大量上消化道出血(9例)或顽固性腹水(2例)。PVTT的诊断基于增强CT和彩色多普勒超声。患者接受了覆膜支架TIPS治疗。分析11例患者的临床特征和平均生存时间。在TIPS前后评估门静脉压力。随访时间为2 - 18个月。

结果

11例患者均成功完成覆膜支架TIPS。门静脉平均压力从32.0 mmHg降至11.8 mmHg(t = 10.756,P = 0.000)。9例患者的消化道出血停止。1例患者的顽固性腹水完全消失,另1例患者的腹水减轻。6例患者出现肝性脑病,经药物治疗后缓解。随访期间,超声显示分流道通畅,症状无复发。9例患者在TIPS后2 - 14个月(平均5.67个月)死亡,均死于多器官功能衰竭。其余2例患者在16个月和18个月随访时仍存活。

结论

对于伴有门静脉主干癌栓的HCC患者,覆膜支架TIPS在技术上是可行的,短期疗效良好。

相似文献

2
Transjugular Intrahepatic Portosystemic Shunt for Portal Hypertension in Hepatocellular Carcinoma with Portal Vein Tumor Thrombus.
Cardiovasc Intervent Radiol. 2017 Sep;40(9):1372-1382. doi: 10.1007/s00270-017-1655-8. Epub 2017 May 9.
6
Transjugular intrahepatic portosystemic shunt creation with the Viatorr expanded polytetrafluoroethylene-covered stent-graft.
J Vasc Interv Radiol. 2004 Mar;15(3):239-48. doi: 10.1097/01.rvi.0000116194.44877.c1.

引用本文的文献

1
Fully Covered Stent-TIPS for Advanced HCC Patients with Portal Vein Tumor Thrombus-Related Severe Symptomatic Portal Hypertension.
J Hepatocell Carcinoma. 2025 Jan 14;12:29-41. doi: 10.2147/JHC.S491153. eCollection 2025.
3
Efficacy and safety of transjugular intrahepatic portosystemic shunt in patients with hepatocellular carcinoma-A systematic review and meta-analysis.
Indian J Gastroenterol. 2024 Dec;43(6):1121-1135. doi: 10.1007/s12664-024-01646-7. Epub 2024 Aug 10.
5
Risks and benefits of TIPS in HCC and other liver malignancies: a literature review.
BMC Gastroenterol. 2023 Nov 20;23(1):403. doi: 10.1186/s12876-023-03047-0.
6
Transjugular intrahepatic portosystemic shunt in patients with hepatocellular carcinoma: A systematic review.
United European Gastroenterol J. 2023 Oct;11(8):733-744. doi: 10.1002/ueg2.12454. Epub 2023 Sep 22.
7
TIPS plus sequential systemic therapy of advanced HCC patients with tumour thrombus-related symptomatic portal hypertension.
Eur Radiol. 2022 Oct;32(10):6777-6787. doi: 10.1007/s00330-022-08705-7. Epub 2022 Apr 20.
8
Transjugular intrahepatic portosystemic shunt for the management of symptomatic malignant pseudocirrhosis.
J Gastrointest Oncol. 2022 Feb;13(1):279-287. doi: 10.21037/jgo-21-501.

本文引用的文献

1
Stent-grafts for the treatment of TIPS dysfunction: fluency stent vs Wallgraft stent.
World J Gastroenterol. 2013 Aug 14;19(30):5000-5. doi: 10.3748/wjg.v19.i30.5000.
2
Clinical outcome and predictors of survival after TIPS insertion in patients with liver cirrhosis.
World J Gastroenterol. 2012 Oct 7;18(37):5211-8. doi: 10.3748/wjg.v18.i37.5211.
3
The transjugular intrahepatic portosystemic shunt: an update.
AJR Am J Roentgenol. 2012 Oct;199(4):746-55. doi: 10.2214/AJR.12.9101.
6
EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma.
J Hepatol. 2012 Apr;56(4):908-43. doi: 10.1016/j.jhep.2011.12.001.
7
Management of HCC.
J Hepatol. 2012;56 Suppl 1:S75-87. doi: 10.1016/S0168-8278(12)60009-9.
8
Transjugular intrahepatic portosystemic shunts in patients with hepatic malignancy.
Semin Intervent Radiol. 2005 Dec;22(4):309-15. doi: 10.1055/s-2005-925557.
10
Early use of TIPS in patients with cirrhosis and variceal bleeding.
N Engl J Med. 2010 Jun 24;362(25):2370-9. doi: 10.1056/NEJMoa0910102.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验